Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Comment by TenFingerson Aug 20, 2018 12:50pm
118 Views
Post# 28487221

RE:RE:RE:RE:Trial Results

RE:RE:RE:RE:Trial ResultsI woud also expect a follow-up to this soon. This news release doesn't talk about WHAT, specifically, their roadmap is for this successful formulation, or if they are just going to sit on it until they can produce it themselves. It just talks about a new trial for felines. I was half expecting an announcement like this to include an application filing announcement with HC. Was a bit surprised by that actually, especially with these positive results.

I know this is a highly competitive space right now, several companies have launched into trials like this. So I expect there is some strategy here to determine their next move carefully, or maybe they file quietly and announce when they get something back from HC.

I feel this news release is just a piece of what is really going on here. Would love to chat with Feldman about this later this week.


TenFingers wrote: If I've learned anything about the patterns of news releases for LIB, it's that they love to fire in waves. :) It wouldn't surprise me to see this tomorrow, or this week for sure.

And what about Signature? That is a wildcard right now that I'm loving.


Ovechkin wrote: Thanks buddy. AOR for JK next 

TenFingers wrote: Also congrats to the LIB team for delivering on time and as expected.

8 months from december 20th - to the DAY. Ovy called it.


TenFingers wrote: This study meets the HC requirements (16 subjects and other parameters).  As far as I can tell, they can immediately apply for a license on this formula as they proceed to secure further formulations to treat other conditions and expand to feline studies.

This is a big card for them. 15 out of 16 subjects benefitted.  We are rounding a corner where pet owners are not going to want to purchase rogue products to treat their fur babies. They want a sanctioned formula. LIB will have it.

 

 

 




<< Previous
Bullboard Posts
Next >>